Aspira Women's Health Inc. (AWHL)

Market Cap	12.59M -19.7%
Revenue (ttm)	8.55M -8.0%
Net Income	-10.01M
EPS	-0.24
Shares Out	46.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251
Open	0.2700
Previous Close	0.3000
Day's Range	0.2700 - 0.2700
52-Week Range	0.2300 - 0.7100
Beta	2.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test tha...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 36
• Stock Exchange: OTCMKTS
• Ticker Symbol: AWHL

Financial Performance

In 2025, Aspira Women's Health's revenue was $9.22 million, an increase of 0.37% compared to the previous year's $9.18 million. Losses were -$12.78 million, -2.40% less than in 2024.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Sep 10, 2026

Data Sources Report a data error